LONDON: Syncona Ltd’s portfolio company Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases has raised £80 million in an oversubscribed Series B financing. Syncona has committed £19.9 million as part of a leading Series B syndicate, led by Sofinnova, in collaboration with Gilde Healthcare, Forbion, and British Patient…
Tag: oversubscribed
Obsidian Therapeutics secures $160.5 million in oversubscribed Series C Funding
CAMBRIDGE: Obsidian Therapeutics, Inc., a trailblazer in engineered cell and gene therapies, has successfully completed a $160.5 million Series C financing round. This round was notably oversubscribed and led by Wellington Management, a new investor in the company. The funding round saw participation from a host of new investors, including Foresite Capital, Janus Henderson Investors,…
Serneke’s rights issue oversubscribed
STOCKHOLM: Serneke Group AB announced that the Company’s subscription ratio in the rights issue amounts to 187 percent. The subscription period for the rights issue ended on 13 January 2021. The final result in the rights issue shows that 3,060,929 series B shares, corresponding to approximately 95.5 per cent of the offered shares, were subscribed…